255 related articles for article (PubMed ID: 26372812)
1. Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Giordano A; Desiderio V; Ghigo D; Caraglia M; De Rosa G; Riganti C
Oncotarget; 2015 Oct; 6(31):31461-78. PubMed ID: 26372812
[TBL] [Abstract][Full Text] [Related]
2. Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors.
Kopecka J; Porto S; Lusa S; Gazzano E; Salzano G; Pinzòn-Daza ML; Giordano A; Desiderio V; Ghigo D; De Rosa G; Caraglia M; Riganti C
Oncotarget; 2016 Apr; 7(15):20753-72. PubMed ID: 26980746
[TBL] [Abstract][Full Text] [Related]
3. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
4. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.
Salaroglio IC; Campia I; Kopecka J; Gazzano E; Orecchia S; Ghigo D; Riganti C
Oncotarget; 2015 Jan; 6(2):1128-42. PubMed ID: 25544757
[TBL] [Abstract][Full Text] [Related]
5. Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells.
Riganti C; Castella B; Kopecka J; Campia I; Coscia M; Pescarmona G; Bosia A; Ghigo D; Massaia M
PLoS One; 2013; 8(4):e60975. PubMed ID: 23593363
[TBL] [Abstract][Full Text] [Related]
6. Basal and therapy-driven hypoxia-inducible factor-1α confers resistance to endocrine therapy in estrogen receptor-positive breast cancer.
Jia X; Hong Q; Lei L; Li D; Li J; Mo M; Wang Y; Shao Z; Shen Z; Cheng J; Liu G
Oncotarget; 2015 Apr; 6(11):8648-62. PubMed ID: 25929338
[TBL] [Abstract][Full Text] [Related]
7. Biofunctionalized polymer-lipid supported mesoporous silica nanoparticles for release of chemotherapeutics in multidrug resistant cancer cells.
Zhang X; Li F; Guo S; Chen X; Wang X; Li J; Gan Y
Biomaterials; 2014 Apr; 35(11):3650-65. PubMed ID: 24462359
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers.
Li YY; Chang JW; Chou WC; Liaw CC; Wang HM; Huang JS; Wang CH; Yeh KY
Lung Cancer; 2008 Feb; 59(2):180-91. PubMed ID: 17900752
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Chang JW; Hsieh JJ; Shen YC; Yeh KY; Wang CH; Li YY; Hsu T
Cancer Lett; 2009 Jun; 278(1):17-26. PubMed ID: 19233551
[TBL] [Abstract][Full Text] [Related]
10. Development of Stemness in Cancer Cell Lines Resistant to the Anticancer Effects of Zoledronic Acid.
Yoshiyama A; Morii T; Ohtsuka K; Ohnishi H; Tajima T; Aoyagi T; Mochizuki K; Satomi K; Ichimura S
Anticancer Res; 2016 Feb; 36(2):625-31. PubMed ID: 26851017
[TBL] [Abstract][Full Text] [Related]
11. Anticancer efficacy of a nitric oxide-modified derivative of bifendate against multidrug-resistant cancer cells.
Ren Z; Gu X; Lu B; Chen Y; Chen G; Feng J; Lin J; Zhang Y; Peng H
J Cell Mol Med; 2016 Jun; 20(6):1095-105. PubMed ID: 26864945
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice.
Lu S; Zhang J; Zhou Z; Liao ML; He WZ; Zhou XY; Li ZM; Xiang JQ; Wang JJ; Chen HQ
Oncol Rep; 2008 Sep; 20(3):581-7. PubMed ID: 18695909
[TBL] [Abstract][Full Text] [Related]
13. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
14. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer.
Milane L; Duan Z; Amiji M
PLoS One; 2011; 6(9):e24075. PubMed ID: 21931642
[TBL] [Abstract][Full Text] [Related]
16. [Inhibition of ABC-transporter(s)' function in non-small cell lung cancer cells by platinum drugs].
Bogush TA; Konukhova AV; Ravcheeva AB; Zabotina TN; Kadagidze ZG; Bogush EA; Komov DV; Polotskiĭ BE; Laktionov KK; Davydov MI
Antibiot Khimioter; 2003; 48(10):11-5. PubMed ID: 15004974
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of zoledronic acid resistance developed in MCF-7 cells.
Kars MD; Işeri OD; Ural AU; Gündüz U
Anticancer Res; 2007; 27(6B):4031-7. PubMed ID: 18225567
[TBL] [Abstract][Full Text] [Related]
18. Wogonin reverses hypoxia resistance of human colon cancer HCT116 cells via downregulation of HIF-1α and glycolysis, by inhibiting PI3K/Akt signaling pathway.
Wang H; Zhao L; Zhu LT; Wang Y; Pan D; Yao J; You QD; Guo QL
Mol Carcinog; 2014 Feb; 53 Suppl 1():E107-18. PubMed ID: 23761018
[TBL] [Abstract][Full Text] [Related]
19. Anticancer activity of SAHA, a potent histone deacetylase inhibitor, in NCI-H460 human large-cell lung carcinoma cells in vitro and in vivo.
Zhao Y; Yu D; Wu H; Liu H; Zhou H; Gu R; Zhang R; Zhang S; Wu G
Int J Oncol; 2014 Feb; 44(2):451-8. PubMed ID: 24297449
[TBL] [Abstract][Full Text] [Related]
20. Afatinib circumvents multidrug resistance via dually inhibiting ATP binding cassette subfamily G member 2 in vitro and in vivo.
Wang XK; To KK; Huang LY; Xu JH; Yang K; Wang F; Huang ZC; Ye S; Fu LW
Oncotarget; 2014 Dec; 5(23):11971-85. PubMed ID: 25436978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
